ANI Pharmaceuticals, Inc. Free Cash Flow 2009–2025
ANI Pharmaceuticals, Inc. reported $171.39M of free cash flow for fiscal 2025. That was 258.7% higher than fiscal 2024. Compared with fiscal 2020, the change was +1776.8%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $171.39M | +258.7% |
| FY 2024 | $47.78M | -56.6% |
| FY 2023 | $110.09M | +374.7% |
| FY 2022 | $-40.08M | -5339.1% |
| FY 2021 | $765,000 | -91.6% |
| FY 2020 | $9.13M | -76.6% |
| FY 2019 | $39.00M | -36.4% |
| FY 2018 | $61.33M | +111.1% |
| FY 2017 | $29.05M | +26.8% |
| FY 2016 | $22.91M | +51.9% |
| FY 2015 | $15.08M | -27.9% |
| FY 2014 | $20.91M | +468.5% |
| FY 2013 | $-5.67M | -1222.8% |
| FY 2012 | $-429,000 | +99.1% |
| FY 2011 | $-48.59M | -21.0% |
| FY 2010 | $-40.16M | -116.0% |
| FY 2009 | $-18.60M | — |
Source: ANI Pharmaceuticals, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open ANIP 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
ANI Pharmaceuticals, Inc. reported $171.39M of free cash flow for fiscal 2025. That was 258.7% higher than fiscal 2024. Compared with fiscal 2020, the change was +1776.8%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for ANI Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeANI Pharmaceuticals, Inc. — frequently asked questions
What is ANI Pharmaceuticals, Inc.'s free cash flow?
ANI Pharmaceuticals, Inc. (ANIP) reported free cash flow of $171.39M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from ANI Pharmaceuticals, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.